A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
City of Hope Medical Center
University of Turin, Italy
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Mayo Clinic
Cancer Trials Ireland
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Mayo Clinic
Gilead Sciences
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
European Myeloma Network B.V.
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Augusta University
Washington University School of Medicine
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Celgene
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
University of California, San Francisco
Hackensack Meridian Health
Essen Biotech
M.D. Anderson Cancer Center
Juno Therapeutics, a Subsidiary of Celgene
Mayo Clinic
University of Arkansas
Medical College of Wisconsin
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Leeds
M.D. Anderson Cancer Center
Fate Therapeutics
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Northside Hospital, Inc.
Brown University
University of Rochester